JP2002513391A - 血管形成の抑制のための方法と組成物 - Google Patents
血管形成の抑制のための方法と組成物Info
- Publication number
- JP2002513391A JP2002513391A JP52172898A JP52172898A JP2002513391A JP 2002513391 A JP2002513391 A JP 2002513391A JP 52172898 A JP52172898 A JP 52172898A JP 52172898 A JP52172898 A JP 52172898A JP 2002513391 A JP2002513391 A JP 2002513391A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- disease
- composition
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.血管形成抑制化合物と消炎剤とを含む血管形成抑制組成物。 2.請求項1に記載の血管形成抑制組成物において、前記消炎剤がステロイドで あることを特徴とする組成物。 3.請求項2に記載の血管形成抑制組成物において、前記ステロイドがコルチソ ル、コルチコステロン、ヒドロコルチソン、ヒドロコルチソル、コルチソン、プ レドニソーン、プレドニソロン、デキサメタゾン、ベクロメタゾン、ベタメタゾ ン、モメタゾン、モメタゾンフロエート、ブデソニド、トリアムシノロンアセト ニド、及び、フルチカソンからなるグループから選ばれることを特徴とする組成 物。 4.請求項1に記載の血管形成抑制組成物において、前記消炎剤が非ステロイド 消炎剤(NSAID)であることを特徴とする組成物。 5.請求項4に記載の血管形成抑制組成物でおいて、前記NSAIDが、アスピリン 、アセトミノフェン、イブプロフェン、エスクレチン、フェニドン、ケルセチン 、ケトプロフェン、ノルジヒドログイアレチン酸(NDGA)、スリンダック、スリン ダックスルフォン、スリンダック硫化物、インドメタシン、NS-398(シクロオキ シゲナーゼ−2抑制剤)、シクロオキシゲナーゼ−1抑制剤、メチルヘプチルイミ ダゾール、フレグレレートナトリウウム、SKF525AHCL、トロムボキサン抑制剤、 トラドール、エカサ、サルサレート、ジフルニサル、メフェナミン酸、ナプロキ セン、ナプロキセンナトリウム、フロクタフェニン、メクロフェナメート、フェ ニルブタゾン、オキシフェンブタゾン、ジクロフェナック、エトドラック、フェ ノプロフェン、フルフェナミン酸、フルルビプロフェン、ピルプロフェン、トル メチン、アパゾン、フェンブフェン、ナブメトン、オキサプロジン、ピロキシカ ム、サリシレート、及び、テノキシカムからなるグループから選ばれることを特 徴とする組成物。 6.請求項5に記載の血管形成抑制組成物において、前記NSAIDがインドメタシ ンとスリンダックから選ばれることを特徴とする組成物。 7.請求項1に記載の血管形成抑制組成物において、前記血管形成抑制化合物が 、以下の(1)〜(3)に示す化合物からなるグループから選ばれることを特徴 とする組成物。 (1)次の化学式から選ばれる化合物; R1〜R4は、それぞれ独立にH;OH;=O;直鎖又は分岐鎖のアルカン、アルケン 、アルキン;環状のアルカン、アルケン及びアルキン;環状と非環状のアルカン 、アルケン及びアルキンの組合せ;非環状、環状、非環状/環状の組合せ部分と 結合するアルコール、アルデヒド、ケトン、カルボン酸、エステル又はエーテル 部分;アザ;アミノ;−XOn又は−O−XOn、X=Nでn=2;X=Sでn=2又は3 ;又はX=Pでn=1〜3;およびハロゲンであり、R5〜R8はそれぞれ独立に以下 から選ばれる: 又は−O−、Yは存在せず、R10=O又はYで、R10はそれぞれ独立してR1と同様で あり、 R9は、次の式からなるグループから選ばれる部分であり、 R11−R17は独立してR5と同様であり、 R18,R19およびR20はそれぞれ独立して以下から選ばれ、 nは1〜4であり、 (2)次の式から選ばれる化合物; R22とR23はそれぞれ独立して、−H、−F、−Cl、−Br、−I、−CH3又は−CH2 −CH3;そしてR24は、−H、−CH3又は−CH2−CH3である。 (3)次の式から選ばれる化合物; Xは上記の(1)で定義されたようにR6である。 8.請求項7に記載の血管形成抑制組成物において、前記血管形成抑制化合物が 次の化学式を有することを特徴とする組成物。 R1〜R4は、請求項8において定義されており、R5とR6は、独立に以下からなる グループより選ばれ、 R9は、F)又はH)から選ばれ、R14とR16はそれぞれ独立に以下からなるグループよ り選ばれ、 9.請求項7に記載の血管形成抑制組成物において、前記血管形成抑制化合物が 次の式からなるグループより選ばれることを特徴とする組成物。 10.請求項7に記載の血管形成抑制組成物において、前記血管形成抑制化合物 が、サリドマイド、サリドマイド代謝物、サリドマイド類似体、サリドマイドの エポキシド、それらの加水分解生成物、EM-12、EM-12の代謝物、EM-12の エポキシド、それらの加水分解生成物、EM-138、EM-138の代謝物、EM-1 38のエポキシド、それらの加水分解生成物、N−フタロイル−DL−グルタミン 酸(PGA)、N−フタロイル−DL−グルタミン酸無水物、及び、それらの混合物から なるグループより選ばれることを特徴とする組成物。 11.請求項10に記載の血管形成抑制組成物において、前記血管形成抑制化合 物が以下の式(I)、(II)及び(III)からなるグループより選ばれること を特徴とする組成物。 Rは、H,(C1−C6)のアルキル、フェニル、及び、ベンゾイルからなるグループ より選ばれ、更にR'がフタリミドとスクシミドからなるグループより選ばれ、 XはCH2又はC=Oであり、 R''は、H、−CH2CH3、−C6H5、−CH2C6H5、−CH2CH=CH2又は であり、 (III)は、(II)の加水分解生成物で、ここに、R''がHで、ピペリジノ環又はピペ リジノ環とイミド環の両方が加水分解される化合物である。 12.請求項10に記載の血管形成抑制組成物において、前記血管形成抑制化合 物が、次の式からなるグループより選ばれることを特徴とする組成物。 13.ヒト又は動物における血管形成を抑制する方法でおいて、非ステロイド消 炎剤(NSAID)を含む組成物をヒト又は動物に投与する工程を含む方法。 14.請求項13に記載の血管形成を抑制する方法でおいて、前記組成物が更に 血管形成抑制化合物を含むことを特徴とする方法。 15.ヒト又は動物における血管形成を抑制する方法でおいて、血管形成抑制化 合物と消炎化合物とを含む組成物をヒト又は動物に投与する工程を含む方法。 16.ヒト又は動物における血管形成存性の病気を治療する方法でおいて、非ス テロイド消炎剤(NSAID)を含む組成物をそのような病気を有するヒト又は動物 に投与する工程を含むこと特徴とする治療法。 17.請求項16に記載の血管形成依存性の病気を治療する方法でおいて、前記 組成物が更に血管形成抑制化合物を含むことを特徴とする治療法。 18.請求項16に記載の血管形成依存性の病気を治療する方法でおいて、前記 血管形成依存性の病気が、黄斑変性、糖尿病網膜症、新生血管性緑内障、水晶体 後方線維増殖症、増殖性硝子体網膜症、ソリッド腫瘍、血液腫瘍、白血病、血管 腫、乾癬、カポジ肉腫、クローン病、潰瘍性大腸炎、癌、未熟児網膜症、角膜移 植拒絶、流行性角結膜炎、ビタミンA欠乏症、コンタクトレンズ過度使用症、ア トピー性角膜炎、上周辺角膜炎、翼状爪膜角膜炎乾燥症、スジョグレン(sjogre n's)症候群、酒さ性座瘡、フィレクテニュロシス(phylectenulosis)、梅毒、ミ コバクテリア感染、リピド変性症、薬品熱傷、細菌性潰瘍、菌性潰瘍、単純疱疹 感染、帯状疱疹感染、原虫感染、カポジ肉腫、モーレン潰瘍、テリエン周辺変性 症、周辺角質溶解、リュウマチ様関節炎、全身狼瘡、多発性動脈炎、外傷、ウェ ーグナー類肉腫症、強膜炎、スティーブン−ジョンソン症候群、放射状角膜切開 、角膜移植拒絶、鎌状赤血球貧血、弾性線維偽性黄血腫、類天疱瘡、パジェット 病、静脈閉鎖、動脈閉鎖、頸動脈障害病、慢性ブドウ膜炎、ライム病、全身狼瘡 紅斑症、イールズ病、ベーチェット症候群、想定眼ヒストプラスマ症、ベスト病 、近視、オプティカル・ピット、シュタルガルト病、扁平部炎、慢性網膜剥離、 過粘稠度症候群、トキソプラズマ病、外傷そしてポスト−レーザー合併症からな るグループから選ばれることを特徴とする治療法。 19.ヒト又は動物における血管形成依存性病気を治療する方法でおいて、血管 形成抑制化合物と消炎剤とを含む組成物をそのような病気を有するヒト又は動物 に投与する工程を含むことを特徴とする治療法。 20.請求項19に記載の血管形成依存性の病気を治療する方法でおいて、前記 血管形成依存性の病気が、黄斑変性、糖尿病網膜症、新生血管性緑内障、水晶体 後方線維増殖症、増殖性硝子体網膜症、ソリッド腫瘍、血液腫瘍、白血病、血管 腫、乾癬、カポジ肉腫、クローン病、潰瘍性大腸炎、癌、朱熟児網膜症、角膜移 植拒絶、流行性角結膜炎、ビタミンA欠乏症、コンタクトレンズ過度使用症、ア トピー性角膜炎、上周辺角膜炎、翼状爪膜角膜炎乾燥症、スジョグレン(sjogre n's)症候群、酒さ性座瘡、フィレクテニュロシス(phylectenulosis)、梅毒、ミ コバクテリア感染、リピド変性症、薬品熱傷、細菌性潰瘍、菌性潰瘍、単純疱疹 感染、帯状疱疹感染、原虫感染、カポジ肉腫、モーレン潰瘍、テリエン周辺変性 症、周辺角質溶解、リュウマチ様関節炎、全身狼瘡、多発性動脈炎、外傷、ウェ ーグナー類肉腫症、強膜炎、スティーブン−ジョンソン症候群、放射状角膜切開 、角膜移植拒絶、鎌状赤血球貧血、弾性線維偽性黄血腫、類天疱瘡、パジェット 病、静脈閉鎖、動脈閉鎖、頸動脈障害病、慢性ブドウ膜炎、ライム病、全身狼瘡 紅斑症、イールズ病、ベーチェット症候群、想定眼ヒストプラスマ症、ベスト病 、近視、オプティカル・ピット、シュタルガルト病、扁平部炎、慢性網膜剥離、 過粘稠度症候群、トキソプラズマ病、外傷そしてポスト−レーザー合併症からな るグループから選ばれることを特徴とする治療法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2870896P | 1996-11-05 | 1996-11-05 | |
US60/028,708 | 1996-11-05 | ||
US96305897A | 1997-11-03 | 1997-11-03 | |
US08/963,058 | 1997-11-03 | ||
PCT/US1997/020116 WO1998019649A2 (en) | 1996-11-05 | 1997-11-04 | Methods and compositions for inhibition of angiogenesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008266428A Division JP5066505B2 (ja) | 1996-11-05 | 2008-10-15 | 血管形成抑制のための方法と組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002513391A true JP2002513391A (ja) | 2002-05-08 |
JP2002513391A5 JP2002513391A5 (ja) | 2005-07-14 |
Family
ID=26703997
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52172898A Withdrawn JP2002513391A (ja) | 1996-11-05 | 1997-11-04 | 血管形成の抑制のための方法と組成物 |
JP2008266428A Expired - Fee Related JP5066505B2 (ja) | 1996-11-05 | 2008-10-15 | 血管形成抑制のための方法と組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008266428A Expired - Fee Related JP5066505B2 (ja) | 1996-11-05 | 2008-10-15 | 血管形成抑制のための方法と組成物 |
Country Status (13)
Country | Link |
---|---|
US (4) | US20030191098A1 (ja) |
EP (5) | EP2143444A1 (ja) |
JP (2) | JP2002513391A (ja) |
AT (3) | ATE305301T1 (ja) |
AU (4) | AU746713B2 (ja) |
CA (2) | CA2270887C (ja) |
DE (3) | DE69734290T2 (ja) |
DK (3) | DK1586322T3 (ja) |
ES (2) | ES2253787T3 (ja) |
HK (2) | HK1028874A1 (ja) |
NZ (1) | NZ336035A (ja) |
PT (2) | PT1586322E (ja) |
WO (1) | WO1998019649A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009191072A (ja) * | 2002-05-17 | 2009-08-27 | Celgene Corp | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
US9101622B2 (en) | 2002-05-17 | 2015-08-11 | Celgene Corporation | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
US10034872B2 (en) | 2014-08-22 | 2018-07-31 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8143283B1 (en) * | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
DK1586322T3 (da) * | 1996-11-05 | 2008-12-01 | Childrens Medical Center | Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer |
NZ509376A (en) * | 1998-07-09 | 2003-10-31 | Francis A Nardella | Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia |
US6235776B1 (en) * | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
US6235782B1 (en) * | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
WO2000027404A1 (en) * | 1998-11-12 | 2000-05-18 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
HUP0200499A3 (en) | 1999-03-18 | 2002-12-28 | Celgene Corp Warren | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use for preparation of pharmaceutical compositions for reducing inflammatory cytokine levels |
EP1178791A2 (en) * | 1999-05-07 | 2002-02-13 | Johns Hopkins University School of Medicine | The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
WO2000072836A2 (en) * | 1999-05-27 | 2000-12-07 | The Rockefeller University | Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
US7105560B1 (en) * | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
US7105172B1 (en) * | 1999-11-18 | 2006-09-12 | Bolla John D | Treatment of rosacea |
CN100479862C (zh) * | 2000-04-03 | 2009-04-22 | 参天制药株式会社 | 释放物质和采用该物质的药物释放系统 |
WO2001085175A2 (en) * | 2000-05-11 | 2001-11-15 | Oklahoma Medical Research Foundation | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
CA2416152A1 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
AU2002253795B2 (en) * | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
IL142037A0 (en) | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
US6344479B1 (en) * | 2001-03-20 | 2002-02-05 | Farmacon-Il, Llc | Method of preventing retinopathy of prematurity in a neonate |
ES2311592T3 (es) * | 2001-03-28 | 2009-02-16 | Santen Pharmaceutical Co., Ltd. | Remedios para enfermedades de retina y coroides que contienen esteroides como principio activo. |
DE60231989D1 (de) * | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
CA2461896C (en) * | 2001-09-28 | 2012-09-18 | Santen Pharmaceutical Co., Ltd. | Injections for eye tissues containing drug bonded to polyethylene glycol |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
CA2504024A1 (en) * | 2002-10-31 | 2004-05-21 | Celgene Corporation | Composition for the treatment of macular degeneration |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7973057B2 (en) | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
KR20060124607A (ko) * | 2003-11-06 | 2006-12-05 | 셀진 코포레이션 | 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물 |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
JP2007530544A (ja) * | 2004-03-22 | 2007-11-01 | セルジーン・コーポレーション | 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物 |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
JP2007532642A (ja) * | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物 |
AU2004319758A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
JP2007533761A (ja) * | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
US7528106B2 (en) * | 2004-06-04 | 2009-05-05 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
US20060111308A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for therapeutic treatment |
ZA200704890B (en) * | 2004-11-23 | 2008-09-25 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
US8211875B2 (en) * | 2005-02-02 | 2012-07-03 | Nexgenix Pharmaceuticals Inc | Local treatment of neurofibromas |
US7442690B2 (en) * | 2005-03-14 | 2008-10-28 | P & L Enterprise Llc | Topical treatment for psoriasis |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
JP4880685B2 (ja) * | 2005-07-22 | 2012-02-22 | ザ プロクター アンド ギャンブル カンパニー | 薬物による不整脈の発生を低減するための組成物 |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
KR101430760B1 (ko) | 2005-10-18 | 2014-08-19 | 알러간, 인코포레이티드 | 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법 |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
EP1974739A1 (en) * | 2007-03-21 | 2008-10-01 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Methods and compounds for modulating inflammatory processes |
US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
BRPI0705396B1 (pt) * | 2007-12-12 | 2021-10-05 | Universidade Estadual De Campinas - Unicamp | Compostos derivados ftalimídicos |
KR20100111291A (ko) | 2008-02-07 | 2010-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법 |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
BRPI0901298A2 (pt) * | 2009-04-06 | 2011-01-04 | Ems Sa | derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias |
US20120295979A1 (en) * | 2011-05-03 | 2012-11-22 | Florida Atlantic University | Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
WO2014160702A1 (en) | 2013-03-25 | 2014-10-02 | Chs Pharma, Inc. | Retinopathy treatment |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
MA40687A (fr) * | 2014-04-10 | 2017-03-28 | Ifom Fondazione St Firc Di Oncologia Molecolare | Méthodes et compositions de traitement de malformation vasculaire |
JP2018527302A (ja) | 2015-06-26 | 2018-09-20 | セルジーン コーポレイション | 免疫調節化合物を用いたカポジ肉腫またはkshv誘発性リンパ腫の治療方法、及びバイオマーカーの使用 |
WO2017081676A1 (en) * | 2015-11-09 | 2017-05-18 | Pharmatwob | Pharmaceutical compositions and methods for treatment of cancer |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
CA3075716A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US11236103B2 (en) | 2018-07-27 | 2022-02-01 | Biotheryx, Inc. | Bifunctional compounds |
JP2022507267A (ja) | 2018-11-13 | 2022-01-18 | バイオセリックス, インコーポレイテッド | 置換イソインドリノン |
KR102143531B1 (ko) * | 2018-12-20 | 2020-08-12 | 영남대학교 산학협력단 | 탈리도마이드를 유효성분으로 함유하는 가축 육질 개선용 조성물 |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
US3560495A (en) * | 1965-05-08 | 1971-02-02 | Ernst Frankus | 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6 |
US3563986A (en) * | 1965-10-12 | 1971-02-16 | Ernst Frankus | 4 - phthalimido - n - heterocyclic amino methyl or piperidino hydrazino piperidine diones 2,6 |
AT278739B (de) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Verfahren zur Herstellung von neuen Anhydriden und Imiden substituierter Dicarbonsäuren |
US3705162A (en) * | 1967-07-01 | 1972-12-05 | Gruenenthal Chemie | 4-phthalimidine glutarimides |
US4552888A (en) * | 1982-01-15 | 1985-11-12 | Eli Lilly And Company | Ascorbic acid ethers in angiogene |
IL67646A0 (en) | 1982-01-15 | 1983-05-15 | Lilly Co Eli | Ascorbic acid ethers and related compounds |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
JP2544136B2 (ja) | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ds4152を含有する血管新生抑制剤及び抗腫瘍剤 |
US4808402A (en) | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
JP2806454B2 (ja) | 1988-01-19 | 1998-09-30 | 武田薬品工業株式会社 | 脈管形成阻止剤 |
US5021404A (en) * | 1988-04-20 | 1991-06-04 | The Children's Medical Center Corporation | Angiostatic collagen modulators |
CA1329771C (en) | 1988-09-01 | 1994-05-24 | Shoji Kishimoto | Angiogenesis inhibitory agent |
GB9000644D0 (en) | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
DE59207778D1 (de) | 1991-04-17 | 1997-02-06 | Gruenenthal Gmbh | Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln |
JPH05310576A (ja) * | 1992-04-30 | 1993-11-22 | Shibuya Miyuki | 抗腫瘍剤 |
US5679696A (en) * | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
CA2094203A1 (en) * | 1993-04-16 | 1994-10-17 | Derek A. Willoughby | Inhibition of angiogenesis |
DE4320157A1 (de) * | 1993-06-18 | 1994-12-22 | Bayer Ag | Verwendung von 1,2,4-Dithiazolium-Salzen als Chemotherapeutica |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
WO1995003807A1 (en) * | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
AU7376494A (en) * | 1993-08-04 | 1995-02-28 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
US5405855A (en) * | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US5443824A (en) * | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
DK1586322T3 (da) * | 1996-11-05 | 2008-12-01 | Childrens Medical Center | Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer |
EP1182709A1 (en) | 2000-08-14 | 2002-02-27 | IPU, Instituttet For Produktudvikling | A process for depositing metal contacts on a buried grid solar cell and a solar cell obtained by the process |
-
1997
- 1997-11-04 DK DK05014759T patent/DK1586322T3/da active
- 1997-11-04 CA CA002270887A patent/CA2270887C/en not_active Expired - Lifetime
- 1997-11-04 DE DE69734290T patent/DE69734290T2/de not_active Expired - Lifetime
- 1997-11-04 PT PT05014759T patent/PT1586322E/pt unknown
- 1997-11-04 DE DE69740095T patent/DE69740095D1/de not_active Expired - Lifetime
- 1997-11-04 ES ES97946884T patent/ES2253787T3/es not_active Expired - Lifetime
- 1997-11-04 ES ES05014759T patent/ES2313154T3/es not_active Expired - Lifetime
- 1997-11-04 EP EP20090174381 patent/EP2143444A1/en not_active Withdrawn
- 1997-11-04 DK DK07121971.1T patent/DK1920773T3/da active
- 1997-11-04 DE DE69738935T patent/DE69738935D1/de not_active Expired - Lifetime
- 1997-11-04 JP JP52172898A patent/JP2002513391A/ja not_active Withdrawn
- 1997-11-04 CA CA2514681A patent/CA2514681C/en not_active Expired - Lifetime
- 1997-11-04 EP EP97946884A patent/EP0963200B9/en not_active Expired - Lifetime
- 1997-11-04 AT AT97946884T patent/ATE305301T1/de active
- 1997-11-04 AU AU51973/98A patent/AU746713B2/en not_active Expired
- 1997-11-04 AT AT07121971T patent/ATE493983T1/de active
- 1997-11-04 NZ NZ336035A patent/NZ336035A/en not_active IP Right Cessation
- 1997-11-04 PT PT07121971T patent/PT1920773E/pt unknown
- 1997-11-04 EP EP10178851A patent/EP2298300A1/en not_active Withdrawn
- 1997-11-04 EP EP07121971A patent/EP1920773B1/en not_active Expired - Lifetime
- 1997-11-04 AT AT05014759T patent/ATE405268T1/de active
- 1997-11-04 EP EP05014759A patent/EP1586322B1/en not_active Expired - Lifetime
- 1997-11-04 WO PCT/US1997/020116 patent/WO1998019649A2/en active IP Right Grant
- 1997-11-04 DK DK97946884T patent/DK0963200T3/da active
-
2000
- 2000-06-14 HK HK00103555A patent/HK1028874A1/xx not_active IP Right Cessation
- 2000-06-14 HK HK06104412A patent/HK1083064A1/xx not_active IP Right Cessation
-
2002
- 2002-03-08 AU AU23191/02A patent/AU780296B2/en not_active Expired
-
2003
- 2003-01-10 US US10/340,554 patent/US20030191098A1/en not_active Abandoned
- 2003-05-05 US US10/430,892 patent/US20040248820A1/en not_active Abandoned
-
2005
- 2005-06-15 AU AU2005202596A patent/AU2005202596B2/en not_active Expired
-
2006
- 2006-04-26 US US11/411,230 patent/US7435745B2/en not_active Expired - Fee Related
-
2008
- 2008-10-10 US US12/249,847 patent/US8039488B2/en not_active Expired - Fee Related
- 2008-10-15 JP JP2008266428A patent/JP5066505B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-18 AU AU2010200186A patent/AU2010200186B2/en not_active Expired
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009191072A (ja) * | 2002-05-17 | 2009-08-27 | Celgene Corp | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
JP2013049734A (ja) * | 2002-05-17 | 2013-03-14 | Celgene Corp | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
US9101622B2 (en) | 2002-05-17 | 2015-08-11 | Celgene Corporation | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
US9101621B2 (en) | 2002-05-17 | 2015-08-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US10206914B2 (en) | 2002-05-17 | 2019-02-19 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US10034872B2 (en) | 2014-08-22 | 2018-07-31 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5066505B2 (ja) | 血管形成抑制のための方法と組成物 | |
KR100506043B1 (ko) | 맥관형성을억제하기위한조성물 | |
US6518298B2 (en) | Methods and compositions for inhibition of angiogenesis with EM-138 | |
US8143283B1 (en) | Methods for treating blood-born tumors with thalidomide | |
JP2008521822A (ja) | 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法 | |
ES2358687T3 (es) | Talidomida y dexametasona para el tratamiento de tumores. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080425 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080617 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20081017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081017 |